The National Collaborative Research Infrastructure Strategy (NCRIS) has developed a package of support for clinical professionals and researchers working in response to COVID-19.
Australians are amongst the leaders in the global life sciences community that are rallying together to tackle this global pandemic. The opportunities presented through NCRIS enables these life science companies to access the world-class infrastructure available in Australia.
Support from 11 NCRIS facilities cover a broad spectrum of research infrastructures, including: Australian Centre for Disease Preparedness (ACDP, CSIRO), Australian Research Data Commons (ARDC), Bioplatforms Australia, Microscopy Australia, National Computational Infrastructure (NCI),Pawsey Supercomputing Centre, Phenomics Australia, Australian National Fabrication Facility (ANFF), Population Health Research Network (PHRN), National Imaging Facility, and Therapeutic Innovation Australia (TIA).
The infrastructure and expertise of the NCRIS network is open to engage and support companies with:
- Vaccine candidate development
- Clinical trial support
- Drug design and discovery
- Design and delivery of customised, genetically engineered (e.g., CRISPR) animal and cell models
- Production of biotherapeutics under Good Manufacturing Practice
- Diagnostic imaging
- DNA and RNA sequencing
- Bioimaging
- Data linkage
- Outcomes monitoring and post-market surveillance
- Personal protective equipment and medical device development
- Computing capability - high performance computing, cloud computing, data analysis and data collections
NCRIS is an initiative of the Australian Government that has resulted from a program of long-term investment in a national network of infrastructures that are mature and ready to respond to active and emerging needs.
Read the fact sheets here.